Skip to content

Ardelyx ARDX Additional Paid-In Capital

Additional Paid-In Capital at other companies

Bausch Health Companies logo
Bausch Health CompaniesBHC
$295M+34.1%
XER
Xeris Biopharma Holdings, Inc.XERS
$682.09M+5.6%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$2.82B+11.3%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$96.87M-4.1%
Mineralys Therapeutics, Inc. logo
Mineralys Therapeutics, Inc.MLYS
$1.13B+65.3%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$2.57B+2.6%

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.53B+25.5%
Enterprise value$1.71B+27.1%
P/S3.6×+0.2×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%
Net margin-13.6%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-39.5%
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Ardelyx’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's additional paid-in capital?
Ardelyx (ARDX) reported additional paid-in capital of $1.13B in Q1 2026.
How has Ardelyx's additional paid-in capital changed year-over-year?
Ardelyx's additional paid-in capital increased by 5.7% year-over-year, from $1.07B to $1.13B.
What is the long-term trend for Ardelyx's additional paid-in capital?
Over 5 years (2020 to 2025), Ardelyx's additional paid-in capital has grown at a 10.3% compound annual growth rate (CAGR), from $680.87M to $1.11B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.